332 related articles for article (PubMed ID: 18046314)
21. Retention of glomerular basement membrane-proteoglycans accompanying loss of anionic site staining in experimental diabetes.
Templeton DM
Lab Invest; 1989 Aug; 61(2):202-11. PubMed ID: 2755078
[TBL] [Abstract][Full Text] [Related]
22. Glomerular heparan sulfate alterations: mechanisms and relevance for proteinuria.
Raats CJ; Van Den Born J; Berden JH
Kidney Int; 2000 Feb; 57(2):385-400. PubMed ID: 10652015
[TBL] [Abstract][Full Text] [Related]
23. Transgenic expression of mammalian heparanase uncovers physiological functions of heparan sulfate in tissue morphogenesis, vascularization, and feeding behavior.
Zcharia E; Metzger S; Chajek-Shaul T; Aingorn H; Elkin M; Friedmann Y; Weinstein T; Li JP; Lindahl U; Vlodavsky I
FASEB J; 2004 Feb; 18(2):252-63. PubMed ID: 14769819
[TBL] [Abstract][Full Text] [Related]
24. Glomerular basement membrane heparan sulfate in health and disease: A regulator of local complement activation.
Borza DB
Matrix Biol; 2017 Jan; 57-58():299-310. PubMed ID: 27609404
[TBL] [Abstract][Full Text] [Related]
25. Breaking down the barrier: evidence against a role for heparan sulfate in glomerular permselectivity.
Harvey SJ; Miner JH
J Am Soc Nephrol; 2007 Mar; 18(3):672-4. PubMed ID: 17301187
[No Abstract] [Full Text] [Related]
26. Presence of heparan sulfate in the glomerular basement membrane.
Kanwar YS; Farquhar MG
Proc Natl Acad Sci U S A; 1979 Mar; 76(3):1303-7. PubMed ID: 155819
[TBL] [Abstract][Full Text] [Related]
27. Changes in heparan sulfate correlate with increased glomerular permeability.
Groggel GC; Stevenson J; Hovingh P; Linker A; Border WA
Kidney Int; 1988 Feb; 33(2):517-23. PubMed ID: 2452273
[TBL] [Abstract][Full Text] [Related]
28. Characterization of heparan sulfate isolated from drug glomerular basement membranes.
Linker A; Hovingh P; Kanwar YS; Farquhar MG
Lab Invest; 1981 Jun; 44(6):560-5. PubMed ID: 6453253
[TBL] [Abstract][Full Text] [Related]
29. Abnormal glomerular permeability characteristics in diabetic nephropathy: implications for the therapeutic use of low-molecular weight heparin.
Lewis EJ; Xu X
Diabetes Care; 2008 Feb; 31 Suppl 2():S202-7. PubMed ID: 18227486
[TBL] [Abstract][Full Text] [Related]
30. Removal of heparan sulfate from the glomerular basement membrane blocks protein passage.
Wijnhoven TJ; Lensen JF; Wismans RG; Lefeber DJ; Rops AL; van der Vlag J; Berden JH; van den Heuvel LP; van Kuppevelt TH
J Am Soc Nephrol; 2007 Dec; 18(12):3119-27. PubMed ID: 18003778
[TBL] [Abstract][Full Text] [Related]
31. Association between heparan sulfate proteoglycan excretion and proteinuria after renal transplantation.
Stefanidis I; Heintz B; Stöcker G; Mrowka C; Sieberth HG; Haubeck HD
J Am Soc Nephrol; 1996 Dec; 7(12):2670-6. PubMed ID: 8989747
[TBL] [Abstract][Full Text] [Related]
32. Heparan sulfate staining of the glomerular basement membrane in relation to circulating anti-DNA and anti-heparan sulfate reactivity: a longitudinal study in NZB/W F1 mice.
Hylkema MN; van Bruggen MC; van de Lagemaat R; Kramers K; Berden JH; Smeenk RJ
J Autoimmun; 1996 Feb; 9(1):41-50. PubMed ID: 8845053
[TBL] [Abstract][Full Text] [Related]
33. Cross-reactivity of human and murine anti-DNA antibodies with heparan sulfate. The major glycosaminoglycan in glomerular basement membranes.
Faaber P; Rijke TP; van de Putte LB; Capel PJ; Berden JH
J Clin Invest; 1986 Jun; 77(6):1824-30. PubMed ID: 2940265
[TBL] [Abstract][Full Text] [Related]
34. Glomerular and urinary heparan sulphate in congenital nephrotic syndrome.
Vermylen C; Levin M; Mossman J; Barratt TM
Pediatr Nephrol; 1989 Apr; 3(2):122-9. PubMed ID: 2534970
[TBL] [Abstract][Full Text] [Related]
35. Increased expression of heparanase in overt diabetic nephropathy.
van den Hoven MJ; Rops AL; Bakker MA; Aten J; Rutjes N; Roestenberg P; Goldschmeding R; Zcharia E; Vlodavsky I; van der Vlag J; Berden JH
Kidney Int; 2006 Dec; 70(12):2100-8. PubMed ID: 17051139
[TBL] [Abstract][Full Text] [Related]
36. Loss of heparan sulfate proteoglycan from glomerular basement membrane of nephrotic rats.
Mynderse LA; Hassell JR; Kleinman HK; Martin GR; Martinez-Hernandez A
Lab Invest; 1983 Mar; 48(3):292-302. PubMed ID: 6219248
[TBL] [Abstract][Full Text] [Related]
37. A functional heparan sulfate mimetic implicates both heparanase and heparan sulfate in tumor angiogenesis and invasion in a mouse model of multistage cancer.
Joyce JA; Freeman C; Meyer-Morse N; Parish CR; Hanahan D
Oncogene; 2005 Jun; 24(25):4037-51. PubMed ID: 15806157
[TBL] [Abstract][Full Text] [Related]
38. Elastase, but not proteinase 3 (PR3), induces proteinuria associated with loss of glomerular basement membrane heparan sulphate after in vivo renal perfusion in rats.
Heeringa P; Van den Born J; Brouwer E; Dolman KM; Klok PA; Huitema MG; Limburg PC; Bakker MA; Berden JH; Daha MR; Kallenberg CG
Clin Exp Immunol; 1996 Aug; 105(2):321-9. PubMed ID: 8706341
[TBL] [Abstract][Full Text] [Related]
39. Decreased glomerular basement membrane heparan sulfate proteoglycan in essential hypertension.
Heintz B; Stöcker G; Mrowka C; Rentz U; Melzer H; Stickeler E; Sieberth HG; Greiling H; Haubeck HD
Hypertension; 1995 Mar; 25(3):399-407. PubMed ID: 7875766
[TBL] [Abstract][Full Text] [Related]
40. Undersulfation of glomerular basement membrane heparan sulfate in experimental diabetes and lack of correction with aldose reductase inhibition.
Cohen MP; Klepser H; Wu VY
Diabetes; 1988 Oct; 37(10):1324-7. PubMed ID: 2970980
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
